Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Compassionate Use of Ropeginterferon-Alfa-2b/P1101 for Treatment of High Risk Polycythemia Vera and Essential Thrombocythemia Patients Previously Controlled on Pegylated Interferon-Alfa-2a/ Pegasys ®

Jeffrey A Gilreath, PharmD, Tsewang Tashi, MD, Soo Jin Kim, MS, Kimberly Hickman, BS, Josef T. Prchal, MD

Blood (2018) 132 (Supplement 1): 5459.

https://doi.org/10.1182/blood-2018-99-116852

Published: 2018

Journal Articles

Single Center Retrospective Study of Essential Thrombocythaemia Diagnosed Patients Treated with Interferon - Benefit and Tolerability

Joana Desterro, Donal P McLornan, MD PhD FRCP FRCPath, Natalia Curto-Garcia, Jennifer O'Sullivan, Kordasti Shahram, Claire Woodley, Yvonne Francis, Deepti Radia, MD, Claire N. Harrison, MD DM, FRCP, PRCPath

Blood (2018) 132 (Supplement 1): 5458.

https://doi.org/10.1182/blood-2018-99-115021

Published: 2018

Journal Articles

Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

Blood (2018) 132 (Supplement 1): 580.

https://doi.org/10.1182/blood-2018-99-111255

Published: 2018

Journal Articles

Pegylated-Interferon Treatment Is Safe and Efficient for Pregnant Patients with Essential Thrombocythaemia

Yan Beauverd, Arvind Pillai, MBBS, MRCP, FRCPath, Steven Knapper, DM BMBCh FRCPath MRCP, Catherine Cargo, MB MRCP FRCPath, Claire N. Harrison, Susan Robinson

Blood (2015) 126 (23): 1613.

https://doi.org/10.1182/blood.V126.23.1613.1613

Published: 2015

Journal Articles

Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAF V600E mutation

Blood (2014) 124 (7): 1119–1126.

https://doi.org/10.1182/blood-2013-12-543793

Published: 2014

Journal Articles

AOP2014/P1101, a Novel Peg-Proline-Interferon Alpha (IFNa) 2b, Specifically Targets JAK2V617F-Positive Polycythemia Vera (PV) Cells

Emmanuelle Verger, PhD, Bruno Cassinat, PharmD, PhD, Annalisa Andreoli, MD, Elodie Lesteven, PharmD, MSc, Christoph Klade, PhD, Oleh Zahriychuk, MD, MSc, Christine Chomienne, MD, PhD, Jean-Jacques Kiladjian, MD, PhD

Blood (2013) 122 (21): 1611.

https://doi.org/10.1182/blood.V122.21.1611.1611

Published: 2013

Journal Articles

Imatinib (IM) and Interferon-Alpha (IFN-a) Maintenance Therapy Is Associated with Long-Term DFS in a Subset of Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Heike Pfeifer, MD, Sylvia Wystub, PhD, A. Binckebanck, Barbara Wassmann, Andreas Käbisch, Michael Lübbert, MD, Lothar Leimer, MD, Aristoteles Giagounidis, MD, Winfried Gassmann, MD, PhD, Patrick Brueck, MD, Hubert Serve, Prof. Dr. med., Dieter Hoelzer, MD, Oliver G. Ottmann, MD

Blood (2012) 120 (21): 1503.

https://doi.org/10.1182/blood.V120.21.1503.1503

Published: 2012

Journal Articles

Pegylated Interferon-Alfa-2a Induces Complete Hematologic and Molecular Responses with Low Toxicity in Essential Thrombocythemia

Mohamed A. Yassin, MBBS, MSc, CABM, FACP, Nader Al-Dewik, BSc, MSc, Hanadi Rafii El-Ayoubi, MD

Blood (2012) 120 (21): 1743.

https://doi.org/10.1182/blood.V120.21.1743.1743

Published: 2012

Journal Articles

Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+ Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group

Eva Kimby, M.D., Ph.D., Björn Östenstad, Peter de Nully Brown, Harald Holte, Jr., MD, PhD, Hans Hagberg, Martin Erlanson, Ola Linden, MD, Marie Nordström, MD, PhD, Christer Sundstrom, MD, PhD

Blood (2012) 120 (21): 794.

https://doi.org/10.1182/blood.V120.21.794.794

Published: 2012

Journal Articles

Using Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) to Evaluate Quality of Life for MPN Patients in Qatar

Mohamed A. Yassin, MBBS, MSc, CABM, FACP, Hanadi Rafii El-Ayoubi, MD, Nader Al-Dewik, BSc, MSc

Blood (2012) 120 (21): 5069.

https://doi.org/10.1182/blood.V120.21.5069.5069

Published: 2012

Journal Articles

Dynamics of Mutant Alleles in Patients with Advanced Essential Thrombocythemia (ET) or Polycythemia (PV) During Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; Pegasys) Therapy

Alfonso Quintas-Cardama, MD, Omar Abdel-Wahab, MD, Ross L Levine, MD, Taghi Manshouri, PhD, Anne-Laure Roupie, Hagop M. Kantarjian, Srdan Verstovsek, MD, PhD

Blood (2011) 118 (21): 281.

https://doi.org/10.1182/blood.V118.21.281.281

Published: 2011

Journal Articles

Pegylated Interferon-Alfa-2a In Clinical Responders Often Decreases JAK2 V617F Allelic Burden and/or Reverses Clonal Hematopoiesis, but These Are Not Always Parallel In PV and ET Females

Sabina Swierczek, PhD, Srdan Verstovsek, MD, PhD, Archana Agarwal, MD, Taghi Manshouri, PhD, Kimberly Hickman, BS, Josef T. Prchal, MD

Blood (2010) 116 (21): 1990.

https://doi.org/10.1182/blood.V116.21.1990.1990

Published: 2010

Journal Articles

High Rates of Molecular Response After Long-Term Follow-up of Patients with Advanced Essential Thrombocythemia (ET) or Polycythemia Vera (PV) Treated with Pegylated Interferon-ALFA-2A (PEG-IFN-α-2A; PEGASYS)

Alfonso Quintás-Cardama, MD, Ross Levine, MD, Taghi Manshouri, Outi Kilpivaara, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD, PhD

Blood (2010) 116 (21): 461.

https://doi.org/10.1182/blood.V116.21.461.461

Published: 2010

Journal Articles

Low-Dose Bexarotene Alone or in Combination for the Treatment of Relapsed or Refractory Cutaneous T-Cell Lymphoma.

Brady Beltran, MD, Antonio Paredes, MD, Celia Moises, MD, Gadwin Sanchez, MD, Lubomir Sokol, MD, PhD, Jorge Castillo, MD

Blood (2009) 114 (22): 4790.

https://doi.org/10.1182/blood.V114.22.4790.4790

Published: 2009

Journal Articles

Pegylated Interferon-ALFA-2A (PEG-IFN-α-2A; PEGASYS) Therapy Renders High Clinical and Molecular Response Rates in Patients with Essential Thrombocythemia (ET) and Polycythemia VERA (PV)

Alfonso Quintas-Cardama, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Jorge Cortes, MD, Marie Ann Richie, Gautam Borthakur, MD, Srdan Verstovsek

Blood (2008) 112 (11): 658.

https://doi.org/10.1182/blood.V112.11.658.658

Published: 2008

Journal Articles

Pml and TAp73 Interacting at Nuclear Body and Activated p38MAPK Mediate Imatinib-Induced p53-Independent Apoptosis of Chronic Myeloid Leukemia Cells

Jin-Hwang Liu, MD, PhD, Chin-Cheng Liu, Chueh-Chuan Yen, Jyh-Pyng Gau, Cheng-Hwai Tzeng

Blood (2008) 112 (11): 5048.

https://doi.org/10.1182/blood.V112.11.5048.5048

Published: 2008

Journal Articles

Low-Dose Bexarotene and Phototherapy or Interferon Alfa-2a in the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Brady Beltran, MD, Antonio Paredes, MD, Celia Moises, MD, Gadwin Sanchez, MD, Luis Riva, MD, Fernando Hurtado, MD, Renzo Salas, MD, Jorge Castillo, MD

Blood (2008) 112 (11): 5010.

https://doi.org/10.1182/blood.V112.11.5010.5010

Published: 2008

Journal Articles

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

Jean-Jacques Kiladjian, Bruno Cassinat, Sylvie Chevret, Pascal Turlure, Nathalie Cambier, Murielle Roussel, Sylvia Bellucci, Bernard Grandchamp, Christine Chomienne, Pierre Fenaux

Blood (2008) 112 (8): 3065–3072.

https://doi.org/10.1182/blood-2008-03-143537

Published: 2008

Journal Articles

Pegylated Interferon-alfa-2a (PEG-IFN-α-2A; PEGASYS™) for Essential Thrombocythemia (ET) and Polycythemia Vera (PV): An Update of an Ongoing Phase II Study.

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, M.D., Guillermo Garcia-Manero, M.D., Jorge Cortes, M.D., Marie Ann Richie, Gautam Borthakur, M.D., Srdan Verstovsek, M.D., Ph.D.

Blood (2007) 110 (11): 3542.

https://doi.org/10.1182/blood.V110.11.3542.3542

Published: 2007

Journal Articles

Treatment with Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; PEGASYS™) for Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV).

Alfonso Quintas-Cardama, MD, Hagop Kantarjian, M.D., Francis Giles, M.D., Jorge Cortes, M.D., Mary Ann Richie, R.N., Gautam Borthakur, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 4884.

https://doi.org/10.1182/blood.V108.11.4884.4884

Published: 2006

NARROW

Compassionate Use of Ropeginterferon-Alfa-2b/P1101 for Treatment of High Risk Polycythemia Vera and Essential Thrombocythemia Patients Previously Controlled on Pegylated Interferon-Alfa-2a/ Pegasys ®

Single Center Retrospective Study of Essential Thrombocythaemia Diagnosed Patients Treated with Interferon - Benefit and Tolerability

Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

Pegylated-Interferon Treatment Is Safe and Efficient for Pregnant Patients with Essential Thrombocythaemia

Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAF V600E mutation

AOP2014/P1101, a Novel Peg-Proline-Interferon Alpha (IFNa) 2b, Specifically Targets JAK2V617F-Positive Polycythemia Vera (PV) Cells

Imatinib (IM) and Interferon-Alpha (IFN-a) Maintenance Therapy Is Associated with Long-Term DFS in a Subset of Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Pegylated Interferon-Alfa-2a Induces Complete Hematologic and Molecular Responses with Low Toxicity in Essential Thrombocythemia

Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+ Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group

Using Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) to Evaluate Quality of Life for MPN Patients in Qatar

Dynamics of Mutant Alleles in Patients with Advanced Essential Thrombocythemia (ET) or Polycythemia (PV) During Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; Pegasys) Therapy

Pegylated Interferon-Alfa-2a In Clinical Responders Often Decreases JAK2 V617F Allelic Burden and/or Reverses Clonal Hematopoiesis, but These Are Not Always Parallel In PV and ET Females

High Rates of Molecular Response After Long-Term Follow-up of Patients with Advanced Essential Thrombocythemia (ET) or Polycythemia Vera (PV) Treated with Pegylated Interferon-ALFA-2A (PEG-IFN-α-2A; PEGASYS)

Low-Dose Bexarotene Alone or in Combination for the Treatment of Relapsed or Refractory Cutaneous T-Cell Lymphoma.

Pegylated Interferon-ALFA-2A (PEG-IFN-α-2A; PEGASYS) Therapy Renders High Clinical and Molecular Response Rates in Patients with Essential Thrombocythemia (ET) and Polycythemia VERA (PV)

Pml and TAp73 Interacting at Nuclear Body and Activated p38MAPK Mediate Imatinib-Induced p53-Independent Apoptosis of Chronic Myeloid Leukemia Cells

Low-Dose Bexarotene and Phototherapy or Interferon Alfa-2a in the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

Pegylated Interferon-alfa-2a (PEG-IFN-α-2A; PEGASYS™) for Essential Thrombocythemia (ET) and Polycythemia Vera (PV): An Update of an Ongoing Phase II Study.

Treatment with Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; PEGASYS™) for Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only